IDKmonitor® Adalimumab Drug Level ELISA K 9657
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 10 µL
Incubation time: 2h 10m
Standard Range: 4.15-225 ng/ml
Size: 96 wells
Regulatory Status: Health Canada Licensed.
Kit Manual: Download
The IDKmonitor® Adalimumab Drug Level ELISA is for the determination of the drug level of adalimumab (e.g. HUMIRA®) and quantitatively measures free adalimumab in EDTA plasma and serum.
Tumor Necrosis Factor-alpha (TNFα) belongs to the proinflammatory cytokines, which promote and sustain inflammatory reactions. It is produced by macrophages and T cells and plays a central role in both acute and chronic inflammations. Consequently, chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, rheumatoid arthritis, or psoriasis are increasingly being treated with antibodies against TNFα, which target directly the underlying inflammatory processes.
The clinical efficacy of an anti-TNFα therapy usually correlates with the trough level of the therapeutic antibody, meaning the drug level just before the next application of the anti-TNFα antibody [2, 3]. Several factors influence the trough level, among them dosage and frequency of anti-TNFα blocker infusion, disease activity, individual pharmacokinetics, and immune reaction (formation of anti-drug antibodies, ADA).
In combination with the detection of ADA against adalimumab, the IDKmonitor® Adalimumab Drug Level ELISA allows treating physicians to monitor and optimize therapy early on.
The IDKmonitor® Adalimumab Drug Level ELISA is Health Canada Licensed.
|Dimensions||6.5 × 10 × 4.5 in|